Female sexual dysfunction: Therapeutic options and experimental challenges

Kyan J. Allahdadi, Rita C A Tostes, R Clinton Webb

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Female sexual dysfunction (FSD) is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. Common symptoms associated with FSD include diminished vaginal lubrication, pain and discomfort upon intercourse, decreased sense of arousal and difficulty in achieving orgasm. Only a small percentage of women seek medical attention. In comparison to the overwhelming research and treatment for erectile dysfunction in males, specifically with the development of phosphodiesterase type 5 inhibitors, significantly less has been explored regarding FSD and treatment is primarily limited to psychological therapy. Several cardiovascular diseases have been linked with FSD including atherosclerosis, peripheral arterial disease and hypertension, all of which are also pathological conditions associated with aging and erectile dysfunction in men. Using animal models, we have expanded our understanding of FSD, however a tremendous amount is still to be learned in order to properly treat women suffering from FSD. The aim of this review is to provide the most current knowledge on FSD, advances in basic science addressing this dysfunction, and explore developing therapeutic options.

Original languageEnglish (US)
Pages (from-to)260-269
Number of pages10
JournalCardiovascular and Hematological Agents in Medicinal Chemistry
Volume7
Issue number4
DOIs
StatePublished - Oct 1 2009

Fingerprint

Erectile Dysfunction
Therapeutics
Orgasm
Lubrication
Phosphodiesterase 5 Inhibitors
Peripheral Arterial Disease
Arousal
Atherosclerosis
Cardiovascular Diseases
Animal Models
Psychology
Hypertension
Pain
Research

Keywords

  • Clitoris
  • Female sexual dysfunction
  • Pudendal arteries
  • Vagina

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology
  • Pharmacology
  • Medicine(all)

Cite this

Female sexual dysfunction : Therapeutic options and experimental challenges. / Allahdadi, Kyan J.; Tostes, Rita C A; Webb, R Clinton.

In: Cardiovascular and Hematological Agents in Medicinal Chemistry, Vol. 7, No. 4, 01.10.2009, p. 260-269.

Research output: Contribution to journalReview article

@article{cd6470d8fe114269a603cd0324bc0c57,
title = "Female sexual dysfunction: Therapeutic options and experimental challenges",
abstract = "Female sexual dysfunction (FSD) is a prevalent problem, afflicting approximately 40{\%} of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. Common symptoms associated with FSD include diminished vaginal lubrication, pain and discomfort upon intercourse, decreased sense of arousal and difficulty in achieving orgasm. Only a small percentage of women seek medical attention. In comparison to the overwhelming research and treatment for erectile dysfunction in males, specifically with the development of phosphodiesterase type 5 inhibitors, significantly less has been explored regarding FSD and treatment is primarily limited to psychological therapy. Several cardiovascular diseases have been linked with FSD including atherosclerosis, peripheral arterial disease and hypertension, all of which are also pathological conditions associated with aging and erectile dysfunction in men. Using animal models, we have expanded our understanding of FSD, however a tremendous amount is still to be learned in order to properly treat women suffering from FSD. The aim of this review is to provide the most current knowledge on FSD, advances in basic science addressing this dysfunction, and explore developing therapeutic options.",
keywords = "Clitoris, Female sexual dysfunction, Pudendal arteries, Vagina",
author = "Allahdadi, {Kyan J.} and Tostes, {Rita C A} and Webb, {R Clinton}",
year = "2009",
month = "10",
day = "1",
doi = "10.2174/187152509789541882",
language = "English (US)",
volume = "7",
pages = "260--269",
journal = "Cardiovascular and Hematological Agents in Medicinal Chemistry",
issn = "1871-5257",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Female sexual dysfunction

T2 - Therapeutic options and experimental challenges

AU - Allahdadi, Kyan J.

AU - Tostes, Rita C A

AU - Webb, R Clinton

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Female sexual dysfunction (FSD) is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. Common symptoms associated with FSD include diminished vaginal lubrication, pain and discomfort upon intercourse, decreased sense of arousal and difficulty in achieving orgasm. Only a small percentage of women seek medical attention. In comparison to the overwhelming research and treatment for erectile dysfunction in males, specifically with the development of phosphodiesterase type 5 inhibitors, significantly less has been explored regarding FSD and treatment is primarily limited to psychological therapy. Several cardiovascular diseases have been linked with FSD including atherosclerosis, peripheral arterial disease and hypertension, all of which are also pathological conditions associated with aging and erectile dysfunction in men. Using animal models, we have expanded our understanding of FSD, however a tremendous amount is still to be learned in order to properly treat women suffering from FSD. The aim of this review is to provide the most current knowledge on FSD, advances in basic science addressing this dysfunction, and explore developing therapeutic options.

AB - Female sexual dysfunction (FSD) is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. Common symptoms associated with FSD include diminished vaginal lubrication, pain and discomfort upon intercourse, decreased sense of arousal and difficulty in achieving orgasm. Only a small percentage of women seek medical attention. In comparison to the overwhelming research and treatment for erectile dysfunction in males, specifically with the development of phosphodiesterase type 5 inhibitors, significantly less has been explored regarding FSD and treatment is primarily limited to psychological therapy. Several cardiovascular diseases have been linked with FSD including atherosclerosis, peripheral arterial disease and hypertension, all of which are also pathological conditions associated with aging and erectile dysfunction in men. Using animal models, we have expanded our understanding of FSD, however a tremendous amount is still to be learned in order to properly treat women suffering from FSD. The aim of this review is to provide the most current knowledge on FSD, advances in basic science addressing this dysfunction, and explore developing therapeutic options.

KW - Clitoris

KW - Female sexual dysfunction

KW - Pudendal arteries

KW - Vagina

UR - http://www.scopus.com/inward/record.url?scp=74049162059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049162059&partnerID=8YFLogxK

U2 - 10.2174/187152509789541882

DO - 10.2174/187152509789541882

M3 - Review article

C2 - 19538161

AN - SCOPUS:74049162059

VL - 7

SP - 260

EP - 269

JO - Cardiovascular and Hematological Agents in Medicinal Chemistry

JF - Cardiovascular and Hematological Agents in Medicinal Chemistry

SN - 1871-5257

IS - 4

ER -